Few cancers have such a readily
available disease marker to follow.
Not exact matches
While rapid point - of - care tests for diagnosing sexually transmitted infections are commercially
available today and used within developing regions, they tend not to be affordable or accurately quantify the concentrations of the
disease markers within a sample, which help to determine the stage of the infection.
SRM - MS analysis will permit us to directly use small - sized samples, such as the individual CSF samples, enable verification of
marker candidates that currently do not have
available antibodies (hence not amenable to conventional analyses such as ELISA or Western blots), and provide robust statistical analyses on individual candidate
markers or combinations of them to determine which would make the best biomarker (s) for a particular
disease condition.
Searches for
markers of
disease genes can be done without genetic maps of the relative order and distance between
markers, but will be more efficient as maps with small distances between
markers (high resolution maps) become
available in the future.